---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-26-000044"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2026-05-15T12:30:17+00:00"
generated_at: "2026-05-15T12:36:01.209791+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Instil Bio reports Q1 2026 cash of $74.7M, GAAP net loss per share $0.62

## Summary
- Cash, equivalents, restricted cash and marketable securities $74.7M as of March 31, 2026; expected to fund operations beyond 2027.
- GAAP net loss per share $0.62; non-GAAP net loss per share $0.32 for Q1 2026.
- R&D expenses $0.7M (down from $5.4M YoY); G&A expenses $5.3M (down from $9.1M).
- Company actively evaluating potential acquisitions and in-licensing opportunities for novel therapeutic candidates.

## SEC filing metadata
- accession: 0001789769-26-000044
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2026-05-15T12:30:17+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000044/0001789769-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000044/til-20260515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-26-000044
- JSON: https://secwatch.observer/filing/0001789769-26-000044.json
- Plain text: https://secwatch.observer/filing/0001789769-26-000044.txt

## Key facts
- Earnings Releases
  Instil Bio, Inc. reported the quarter ended March 31, 2026 results: EPS Net loss per share, basic and diluted was $0.62 for the three months ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - EPS: Net loss per share, basic and diluted was $0.62 for the three months ended March 31, 2026
  - Result: reported results
  source text: Net loss per share, basic and diluted was $0.62 for the three months ended March 31, 2026, compared to $4.32 for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000044/0001789769-26-000044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.